[HTML][HTML] Nanomedicine review: Clinical developments in liposomal applications

E Beltrán-Gracia, A López-Camacho… - Cancer …, 2019 - Springer
Background In recent years, disease treatment has evolved strategies that require increase
in pharmaceutical agent's efficacy and selectivity while decreasing their toxicity in normal …

[HTML][HTML] Liposomal drug delivery systems and anticancer drugs

TOB Olusanya, RR Haj Ahmad, DM Ibegbu, JR Smith… - Molecules, 2018 - mdpi.com
Cancer is a life-threatening disease contributing to~ 3.4 million deaths worldwide. There are
various causes of cancer, such as smoking, being overweight or obese, intake of processed …

[HTML][HTML] Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012

M Rasche, M Zimmermann, L Borschel, JP Bourquin… - Leukemia, 2018 - nature.com
Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in
recent decades. However, it remained unknown whether advances in first-line treatment …

Collaborative efforts driving progress in pediatric acute myeloid leukemia

CM Zwaan, EA Kolb, D Reinhardt… - Journal of clinical …, 2015 - ascopubs.org
Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

[HTML][HTML] Pediatric acute myeloid leukemia—past, present, and future

D Reinhardt, E Antoniou, K Waack - Journal of clinical medicine, 2022 - mdpi.com
JCM | Free Full-Text | Pediatric Acute Myeloid Leukemia—Past, Present, and Future Next
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …

[HTML][HTML] Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology …

R Aplenc, S Meshinchi, L Sung, T Alonzo, J Choi… - …, 2020 - ncbi.nlm.nih.gov
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce
disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase …

[HTML][HTML] Pediatric AML: from biology to clinical management

JDE De Rooij, CM Zwaan… - Journal of clinical …, 2015 - mdpi.com
Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …

Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy

CW Elgarten, R Aplenc - Current Opinion in Pediatrics, 2020 - journals.lww.com
Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

A concise review on cancer treatment methods and delivery systems

E Bidram, Y Esmaeili, H Ranji-Burachaloo… - Journal of Drug Delivery …, 2019 - Elsevier
The ultimate purpose of current cancer research is to develop a comprehensive treatment for
cancer. Recent studies have shown an increased interest in investigating the capacity of …

Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A …

RE van Weelderen, K Klein, CJ Harrison… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE A previous study by the International Berlin-Frankfurt-Münster Study Group (I-
BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic …